Basepath Health + Children's Mercy — Cell and Gene Therapy Partnership

Children's Mercy partners with Basepath Health to expand delivery of pediatric cell and gene therapies. Commercial/clinical partnership — no capital amount disclosed.

The Deal

Children's Mercy announced on May 18, 2026 that it is partnering with Basepath Health to expand delivery of pediatric cell and gene therapies. Basepath provides an AI-native operating platform for advanced therapies, and the collaboration combines workflow automation with longitudinal patient navigation to help Children's Mercy scale these programs across multiple disease states and care settings. The stated goal is to reduce operational burden on clinical teams while increasing capacity for complex pediatric patients.

Context

This clears the partnership bar because it is not a routine hospital customer win. It ties a pediatric health system to a specialized advanced-therapy infrastructure vendor at a moment when cell and gene therapy delivery is shifting from one-off academic-center capability to repeatable operational discipline. For maternal-pediatric health tech, the strategic signal is that software and navigation layers for rare-disease and specialty pediatric care are becoming part of the commercialization stack, especially where providers need payer alignment, manufacturer coordination, and long-term outcomes tracking.

Sources

• PR Newswire: Children's Mercy Partners with Basepath Health to Expand Delivery of Life-Changing Cell and Gene Therapies